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ABSTRACT
Considerable evidence supports the idea that stem-like cells may play an essential 
role during the development of colorectal cancer (CRC). To accomplish this aim, we 
use immunohistochemistry (IHC) and double IHC with different potential stem-like 
markers, anti-musashi (Msi), anti-CD133, anti- LGR5 and anti-ALDH1 to examine the 
presentation of stem-like cells in different compartments including adenoma/CRC 
epithelium, transitional crypts and tumor stroma in colorectal adenoma and CRC. The 
results showed that cells positive for stem-like markers were remarkably increased in 
number and frequently observed in the adenoma/CRC epithelium, transitional crypts 
and tumor stroma. Notably, the population of cells positive for stem-liker markers was 
expanded from the base to the middle part of the transitional crypt in both adenoma 
and CRC tissues, reflecting that stem-like cells are likely involved in the process of 
colorectal tumorigenesis. Counting results showed that the grading scores of cells 
positive for LGR5 and ALDH1 in the adenoma/CRC epithelium were significantly 
increased relative with the control epithelium, and associated with the degree of 
dysplasia in the adenoma and node involvement in the CRC (all P < 0.05). In addition, 
the density of cells positive for stem–like markers in the adenomatous/cancerous 
stroma was also increased and paralleled an increase in the density of proliferative 
stromal cells labeled by PCNA, which were primarily identified as vimentin positive 
fibroblasts. Our results have revealed a changed temporal and spatial presentation 
of stem-like markers in different stages of human colorectal adenoma-carcinoma 
sequence, which might be a hallmark of the adenoma-carcinoma transition.
INTRODUCTION
Colorectal cancer (CRC) is the fourth most frequent 
cancer and has a high mortality rate worldwide. Most 
CRCs, according to the adenoma-carcinoma sequence 
theory, develop from preformed adenoma polyps. The 
malignant potential of an adenomatous polyp is associated 
with its size, dysplastic degree and severity of atypia. 
This adenoma-carcinoma sequence provides an ideal 
opportunity to investigate the changes that occur during 
the development of CRC. Although many molecular, 
genetic and immunological alterations that are involved 
in this sequence have been identified [1–3], the exact 
mechanisms of the adenoma-carcinoma transition are still 
not fully understood.
Recent studies have provided considerable 
evidence to support the hypothesis that human tumors are 
derived from a subpopulation of cells with stem-like cell 
properties, termed tumor stem cells [1, 2]. Tumor stem-
like cells have the capacity to self-renew, differentiate 
and drive tumorigenic growth [2]. The existence of tumor 
stem-like cells in precancerous adenomas as well as in 
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CRCs have been described by several groups [2–10]. An 
association between the tumor stem-like cells and the 
prognosis of patients with CRC has also been suggested 
[11, 12]. During cancer initiation, the changes of tumor 
stem-like cells from precancerous to cancerous lesions 
are of particular interest because the alternation of tumor 
stem-like cells may be one of the hallmarks for colorectal 
tumorigenesis [10, 13, 14]. The histological identification 
of stem-like cells in either tumor or non-tumor tissues 
relies largely on specific markers. Several putative 
markers i.e., Musashi (Msi), CD44, CD133, leucine-rich 
repeat-containing G-protein-coupled receptor 5 (LGR5) 
and aldehyde dehydrogenase 1 (ALDH1) have been used 
to identify tumor stem-like cells in CRCs [2–9]. However, 
previous studies have primarily examined the presentation 
of stem-like markers in established adenomatous/
cancerous epithelium; temporal and spatial variation 
of stem-like markers in different stages of colorectal 
adenoma-carcinoma sequence have not been well studied. 
Given the above background, we hypothesized that 
an altered temporal and spatial presentation of stem-like 
markers could be an important hallmark that reflects the 
ongoing tumorigenesis in colorectum. In this study, we 
have therefore used different stem-like markers, Msi, 
CD133, LGR5 and ALDH1 to investigate the presentation 
of stem-like cells in the different compartment and 
histological stages of the colorectal adenoma–carcinoma 
sequence. 
RESULTS
Stem-like markers in the adenomatous/cancerous 
epithelium
The presence of stem-like markers in different stages 
of the adenoma-carcinoma sequence was evaluated with 
IHC using Msi, CD133, LGR5 and ALDH1 antibodies 
(Figure 1). The results showed that in normal controls, a 
few stem-like marker (Msi, CD133, LGR5 and ALDH1) 
positive cells were at the base of normal colonic crypts 
(Figure 1A). In the adenomatous epithelium, the cells 
positive for stem-like markers were expressed in a patchy 
distribution pattern on the surface of the adenomatous 
crypt (Figure 1B), In the cancerous epithelium, the cells 
positive for stem-like markers were also distributed in 
a diffused pattern (Figure 1C) or in the surface of CRC 
epithelium (Figure 1F) as reported in the literature [5]. 
Because LGR5 and ALDH1 are the two most 
promising and established stem-like markers in adenoma/
CRC, we examined the immunoreactivity of LGR5 and 
ALDH1 in the adenoma/CRC epithelium with semi-
quantitative analysis. The percentage of cells positive 
for LGR5 and ALDH1 in the adenomatous epithelium 
was 39.47% (15/38) and 47.37% (18/38), respectively. 
Additionally, the percentage of cells positive for LGR5 and 
ALDH1 in the CRC epithelium was 63.33% (19/30) and 
66.67% (20/30), respectively. The positive rate for LGR5 
and ALDH1 in the CRC epithelium were slightly higher 
than that in the adenomatous epithelium (both P > 0.05).
Then, the grading scores of LGR5 positive and 
ALDH1 positive cells in the adenomatous/cancerous 
epithelium were analyzed against clinical pathological 
parameters in adenomas and CRCs. In the adenoma, the 
grading scores of LGR5 positive and ALDH1 positive 
cells were correlated with degree of dysplasia (low-grade 
dysplasia vs. high-grade dysplasia; LGR5: 1.26 ± 0.10 
vs. 166 ± 0.12; ALDH1: 1.52 ± 0.11 vs. 1.98 ± 0.14; both 
P < 0.05 by the Mann–Whitney test), but not with 
histological types (data not shown). In the CRC, the 
grading scores of both LGR5 positive and ALDH1 
positive cells were associated with node involvement 
(node negative vs. node positive: LGR5, 1.44 ± 0.13 vs. 
2.18 ± 0.24; ALDH1, 1.74 ± 0.13 vs. 2.40 ± 0.20: both 
P < 0.05 by the Mann–Whitney test). Both of LGR5 and 
ALDH1 grading scores were higher in CRC patients with 
advanced TNM stage than those with early stage (TNM stage 
I vs. II vs. III + VI: LGR5, 1.40  ± 0.17 vs. 1.43  ± 0.15 vs. 
2.27 ± 0.26, P < 0.05; ALDH1, 1.60  ± 0.19 vs. 1.83  ± 0.16 
vs. 2.29 ± 0.19, P > 0.05; both by the Kruskal-Wallis test). 
Changed presentation pattern of cells positive 
for stem–like markers in the transitional crypts 
close to adenomas and CRCs 
Notably, in those sections with transitional crypts 
(6 of 30 adenoma sections, 5 of 30 CRC sections), a 
changed presentation pattern of cells positive for stem–
like markers (Msi, CD133, LGR5 and ALDH1) was 
observed (see Figure 2). The location of cells positive 
for stem-like markers Msi, CD133, LGR5 and ALDH1 
was expanded, often from the base to the middle part and 
occasionally to the top of the transitional crypt close to 
adenomas and CRCs (transitional crypt in adenomas, see 
Figure 2A, 2C, 2E and 2G; transitional crypt in CRCs, 
see Figure 2B, 2D, 2F and 2H). Those observations 
strongly suggested that expanding pathway of stem-like 
cells is from the base to the top during the development 
of adenomas and CRCs.
Increased mesenchymal cells positive for stem-
like markers in adenomatous/cancerous tumor 
stroma
Mesenchymal stem-like cells resided in the tumor 
stroma play a critical role in forming a supportive 
environment for cancer growth and metastasis [21, 22]. In 
normal controls, the cells positive for stem-like markers 
could be observed in the lamina propria. The cells positive 
for stem-like markers Msi, CD133, LGR5 and ALDH1 
were diffusely distributed, and the density of positive 
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cells in lamina propria was higher than that in the crypt 
(Figure 3A, 3D, 3G and 3J). In adenoma tissues, the cells 
positive for stem-like markers were diffusely distributed 
in the tumor stroma between adenomatous epithelium 
(Figure 3B, 3E, 3H and 3J). In CRC tissue, the distribution 
pattern of cells positive for stem-like markers in tumor 
stroma (see Figure 3C, 3F, 3I and 3L) was very similar 
to that in adenomas. However, counting results showed 
that the densities of cells positive for stem-like markers 
LGR5 (Figure 4A) and ALDH1 (Figure 4B) in CRC tumor 
stroma were slightly higher than that in adenomas.
Then, the grading scores of LGR5 positive and 
ALDH1 positive cells in the adenomatous/cancerous stroma 
were analyzed against clinical pathological parameters. In 
the adenoma stroma, the grading scores of LGR5 positive 
and ALDH1 positive cells were not correlated with degree of 
dysplasia or histological types (data not shown). In the CRC 
stroma, the grading scores of LGR5 positive and ALDH1 
positive cells were not associated with TNM stages (NM stage 
I vs. II vs. III + VI: LGR5, 16.86 ± 1.87 vs. 15.18 ± 1.52 vs. 
6.11 ± 2.45, P > 0.05; ALDH1, 18.71 ± 2.69 vs. 20.36 ± 2.16 
vs. 18.78 ± 2.15, P > 0.05; both by the Kruskal-Wallis test). 
However, we have found that although the difference did not 
reach statistical significance, the density grading scores were 
higher in CRC patients with node involvement than those 
without (node negative vs. node positive: LGR5, 14.89 ± 1.20 
Figure 1: The presentation of stem-like markers Msi, CD133, LGR5 and ALDH1 in different stages of the adenoma-
carcinomas evaluated with IHCs. In normal controls, a few cells positive for stem-like markers were shown at the base of normal 
colonic crypts (Figure 1A, 1E, 1I and 1M). In the adenomatous epithelium, the cells positive for stem-like markers were expressed as a 
patchy destruction pattern in the surface of adenomatous crypt (Figure 1B, 1F, 1J and 1N), In the CRC epithelium, the cells positive for 
stem-like markers were also distributed in a diffusely pattern (Figure 1C, 1G, 1K and 1O). In sections with isotype-matched negative 
control antibodies staining (Figure 1D, 1H, 1L and 1P), no any positive cells were found. 
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Figure 2: Changed presentation pattern of stem–like markers in the transitional crypts close to adenomas and CRCs. 
In transitional crypts close to adenomas and CRCs, a changed presentation pattern of stem–like markers was observed. The populations 
of cells positive for stem-like markers Msi, CD133, LGR5 and ALDH1 were expanded, often from the base to the middle part, or even 
higher part of the transitional crypt (transitional crypt in adenomas, see Figure 2A, 2C, 2E and 2G; transitional crypt in CRCs, see 
Figure 2B, 2D, 2F and 2H). 
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vs. 18.00 ± 2.19; ALDH1, 18.00 ± 1.37 vs. 22.22 ± 2.59; both 
P < 0.05 by the Mann–Whitney test). 
Increase in cells positive for stem-like markers 
in the adenomatous/cancerous stroma was 
accompanied by an increase in PCNA-positive 
proliferative cells that consisted primarily of 
fibroblasts 
Tumor stroma and contributes to the cancer 
initiation and progression [23]. We therefore 
investigated proliferation activity of stromal cells in the 
adenomatous/CRC stroma. Along with the increase in 
cells positive for stem-like markers in the tumor stroma, 
the number of proliferative cells in the adenomatous/
cancerous tumor stroma was also significantly increased. 
The proliferation rate in the tumor stromal cells was 
evaluated with PCNA IHC (Figure 5A–5C). The 
results showed that the proliferation rate increased in 
both adenomatous and cancerous tumor stromal cells 
compared to controls (Figure 5G) (both P < 0.0001 
by the Mann–Whitney test). No significant increase in 
proliferation rate was observed between adenoma and 
CRC stroma (P > 0.05).
Figure 3: Mesenchymal stem-like markers in the adenomatous/cancerous tumor stroma. The stromal cells positive for 
stem-like markers were diffusely distributed and the numbers of cells positive for stem-like markers Msi, CD133, LGR5 and ALDH1 
in normal lamina propria and the densities were higher than that in the crypt (Figure 3A, 3D, 3G and 3J). In both the adenomas and 
CRC stroma, the cells positive for stem-like markers were increased and diffusely distributed in the tumor stroma between adenomatous 
(Figure 3B, 3E, 3H and 3J) or CRC (Figure 3C, 3F, 3I and 3L) epithelium. 
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Because fibroblasts are the main type of stromal 
cells and the activation of stromal fibroblasts are 
involved in the initiation and progression of CRC [23, 
24], we examined the expression of fibroblasts labeled 
with vimentin with IHC and the proliferative activity 
of vimentin positive fibroblasts with double IHC in the 
adenoma/CRC stroma. The results of vimentin IHC 
showed that fibroblasts were observed in the whole 
stroma within both the pericryptal and non-pericryptal 
regions in adenoma, CRC and control group sections 
(Figure 5D–5F). In the adenoma section, dense fibroblasts 
were observed in the whole stroma but were particularly 
dense in the peri-adenomatous epithelium region (Figure 
5E) compared to controls (Figure 5D). In the CRC 
sections, the presentation of fibroblasts was similar 
to that of the adenomas and many fibroblasts could be 
found in the tumor stroma (Figure 5F). When the density 
of vimentin positive fibroblasts was graded, the grading 
scores were higher in adenomas (Figure 5H, grey bar) 
and CRCs (Figure 5H, black bar) relative to controls 
(Figure 5H, white bar), although statistical significance 
was not reached.
The results of double IHC demonstrated that many 
of the PCNA positive cells in the control (Figure 6A), 
adenoma (Figure 6B) and CRC (Figure 6C) stromal cells 
were vimentin positive fibroblasts and confirmed that 
vimentin positive fibroblasts in the adenoma/CRC stroma 
might have a high proliferative capacity.
Figure 4: Graphic analysis of the density of mesenchymal stem-like cells labeled by LGR5 and ALDH1 in the 
adenomatous/cancerous tumor stroma. The densities of mesenchymal stem-like cells labeled by LGR5 (Figure 4A)  and ALDH1 
(Figure 4B) were increased in the adenoma and CRC sections relative with the control section, that began from the adenoma lesion and 
even higher in the CRC lesion. 
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DISCUSSION
In this study, we examined the presentation pattern 
of stem-like markers in different stages and compartments 
of the adenoma-carcinoma sequence and translational 
crypts adjacent to adenomas and CRCs. We were able to 
demonstrate an altered localization and expression pattern 
of cells positive for stem-like markers in those tissues. 
In addition, we have also observed an increase in cells 
positive for stem-like markers in the adenoma/CRC stroma 
that accompanied by an active proliferation rate in the 
tumor stromal cells, and many of the proliferative stromal 
cells were identified as vimentin positive fibroblasts. 
These findings suggest that the change in the presentation 
pattern of the stem-like markers in different stages and 
compartments of the adenoma-carcinoma sequence reflects 
an ongoing tumorigenesis. Such change might be one of 
the hallmarks of colorectal tumorigenesis and related to 
the stromal response that resulted from tumorigenesis.
Under physiological conditions, only a low density 
of cells positive for stem-like markers reside in the base of 
crypts, and they play an important role in maintaining normal 
Figure 5: Increased proliferation rate of stromal cells that primarily identified as vimentin positive fibroblasts in 
adenomas and CRCs. The proliferation rate in the tumor stromal cells was evaluated with PCNA IHC (Figure 5A–5C). The stromal 
cells positive for PCNA in both the adenoma and the CRC were significantly increased relative to the control (Figure 5G) (both P < 0.0001). 
Further IHC examination revealed that fibroblasts labeled by vimentin were observed within both the pericryptal and non-pericryptal 
regions in the stroma of control (Figure 5D), adenoma (Figure 5E) and CRC (Figure 5F). When the density of fibroblasts was graded, the 
grading scores were shown in a non-statistically increased in the adenoma (Figure 5H, grey bar) and CRC stroma (Figure 5H, black bar) 
relative to the control (Figure 5H, white bar). 
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tissue homeostasis and function. Thus, it is not unusual that 
the number of cells positive for stem-like markers in the 
normal crypt and lamina propria was low in control tissues. 
However, when colorectal mucosa becomes tumorigenic, the 
stem-like cells are activated and the number of cells positive 
for stem-like markers was significantly increased. In the 
current study, we observed a large change in the presentation 
of stem-like markers in different compartments of adenoma 
and CRC tissues. The cells positive for various types of 
stem-like markers were observed in both the adenomatous/
cancerous epithelium and the tumor stroma. The cells were 
mostly distributed in a patchy pattern in the adenomatous/
cancerous epithelium. This finding might reflect the fact that 
stem cells are substantially activated during the procession 
of colorectal tumorigenesis. 
The importance of stem cells in the initiating of 
adenomas has been recognized [2, 5, 11]. Several potential 
stem-like markers have been used to identify stem cells 
in adenomas/CRC. LGR5 and ALDH1 are the two most 
promising and established stem-like markers and have 
been frequently used [3, 5, 7, 10, 15]. Studies have 
reported that LGR5 and ALDH1 expression can reflect the 
changes in stem-like cells during the process of colorectal 
tumorigenesis. However, whether the mechanism is top-
down or bottom-up is a matter of debate [11, 16]. Some 
studies suggest that dysplastic cells are routinely found 
at the luminal surface of adenomatous crypts that contain 
genetic alterations in the adenomatous polyposis coli 
(APC) gene and neoplasia-associated patterns of gene 
expression. Stem-like cells are also observed at the luminal 
surface of adenomatous crypts. Thus, these findings 
imply that the development of adenomatous polyps 
proceeds through a top-down mechanism. Alternatively, 
genetically-altered cells in the superficial portions of the 
mucosae spread laterally and downward to form new 
crypts that first connect to preexisting normal crypts 
and eventually replace them [17]. However, evidence 
from other studies has supported the idea that colorectal 
polyps are polyclonal and arise from a combination of 
host genetic features via a bottom-up mechanism [18, 19]. 
The transitional mucosa is characterized morphologically 
by an increase in mucosal thickness, lengthening of the 
crypts and goblet cell hyperplasia. Since transitional 
mucosa reflects the ongoing histopathological procession 
of tumorigenesis, studying the changes of pathological 
aspects inside crypts might provide critical information 
for the understanding of tumorigenesis procession. Indeed, 
several groups including ours have demonstrated the 
histological, genetic, histochemical and immunological 
changes in the mucosa adjacent to the adenoma and 
CRC epithelium [20–25]. However, there is very limited 
information available regarding the change of stem-like 
cells in the transitional mucosa during the development 
of CRC. To our best knowledge, the current study is the 
first of its kind to demonstrate the temporal and spatial 
changes of stem-like markers in the transitional mucosa 
from colorectal adenomas to sporadic CRCs. We have 
observed an altered presentation pattern of cells positive 
for stem-like markers in the transitional mucosa close to 
adenomas and CRCs. In controls, cells positive to stem-
like markers were only located at the base of the crypts. 
However, some of positive cells were located in the 
middle part and occasionally expanded to the top of the 
transitional crypt close to adenomas and CRCs. In light 
of our results, such altered location of cells positive for 
stem-like markers in the transitional mucosa may reflect 
the undergoing expanding path of stem-like cells inside 
preneoplasic crypts and could be the supportive evidence 
for the bottom-up hypothesis. This information could also 
be very useful as an indicator of a malignancy potential 
and as a target for novel therapeutic approaches. 
With respect to the relationship between stem-
like cells (labeled with LGR 5 and ALDH1) and 
clinicopathological parameters of patients with adenomas 
Figure 6: Double IHCs confirmed that fibroblasts in the adenoma/CRC stroma might have a high proliferative 
capacity. The results of double IHC demonstrated that many of PCNA positive stromal cells in the control (Figure 6A), adenomas 
(Figure 6B) and CRCs (Figure 6C) were fibroblasts. 
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and CRCs, we have observed slight increased scores of 
LGR5 and ALDH1 positive cells in the adenomatous 
epithelium with high degree of dysplasia. We have also 
found that grading scores of LGR5 and ALDH1 positive 
cells in the cancerous epithelium were significantly 
increased in CRC patients with advanced TNM stages 
than those with early stages. Those observations are 
consist with other groups’ findings [15, 26–32], and 
imply that increased stem-like cell density might be the 
potential predicators for disease stage progression in both 
the adenoma and CRC. Mesenchymal stem like cell can 
be observed in the tumor stroma, it plays a critical role 
in remodeling tumor stroma and forming a supportive 
environment for cancer growth and metastasis [33]. In 
this study, many mesenchymal cells positive for these 
potential stem-like markers could be observed in the 
adenoma/CRC stroma, which was accompanied by an 
increase in proliferation in the stromal cells that has 
been previously reported by our group [34]. When the 
cell positive for stem-like markers was analyzed against 
the clinical pathological parameters in the adenomatous/
cancerous stroma, we have observed that the grading score 
of cell positive for LGR5 and ALDH1 was not associated 
with most clinical pathological parameters i.e. degree of 
dysplasia and histological types in the adenoma and TNM 
stage in the CRC. However, the density grading scores 
of positive cell were higher in CRC patients with node 
involvement than those without, although the difference 
did not reach statistical significance. This observation 
suggested that the tumorigenesis may results in a 
general stem-like cell response in the tumor stroma, such 
activation might contribute to the diseases progression. 
Since vimentin-expression is one of the hallmarks 
of epithelial-mesenchymal-transition (EMT) during 
the progression of CRC, we have therefore further 
examined the activity of vimentin positive fibroblasts in 
the adenomatous/cancerous stroma. The results showed 
that these PCNA positive proliferative stromal cells 
were mostly identified as vimentin positive fibroblasts 
in the adenoma/CRC stroma. As illustrated by many 
studies [1, 34–36], fibroblasts are the main type of 
stromal cells in adenoma and CRC tissue and they 
promote the progression of adenoma to CRC. The exact 
mechanisms for the elevated proliferation seen in tumor 
stromal fibroblasts are thus far undetermined. It has been 
reported that vimentin-expression is one of the hallmarks 
of EMT during the progression of CRC and vimentin 
positive stromal cells may be with tumorigenic cell 
characteristics and play a vital role during the invasion 
of CRC. In addition, many factors are related to the 
stromal activation during the development of human 
cancers [14, 35]. For instance, the release of cytokines 
from the tumor microenvironment may participate in the 
modulation of the proliferative activity of the stromal 
cell [37]. In our previous studies, we have demonstrated 
an elevated expression pattern of IL-17A in the tumor 
microenvironment of adenoma/CRC [25, 38, 39]. It has 
been found that IL-17A stimulates stem-like cells and 
promote the development of various types of cancers 
[40–43]. Our current findings may provide further 
evidence to support the notion that the activation of 
vimentin positive fibroblasts in the adenomatous/cancerous 
stroma might be one of the hallmarks of EMT and are 
involved in the process of colorectal tumorigenesis. 
In summary, this study showed a temporal and spatial 
variation of stem-like markers in different compartments 
and stages of the colorectal adenoma-carcinoma sequence, 
including adenoma/CRC epithelium, transitional crypts 
and tumor stroma, throughout all stages of the colorectal 
adenoma-carcinoma sequence. Such dynamic change of 
stem-like markers reflect the ongoing tumorigenesis and 
may be a hallmark of the adenoma-carcinoma transition.
MATERIALS AND METHODS
A total of 30 biopsies of colorectal adenomas excised 
completely by endoscopic polypectomy (male/female ratio 
22/8; age 36–70 years) and 30 biopsies of CRC excised by 
surgery (male/female ratio 17/13; age 49–70 years) were 
included in this study. No patients received radiotherapy 
and/or chemotherapy preoperatively. Moreover, biopsies 
from 12 subjects (male 8, female 4, ages 35–60 years) 
with normal colonoscopy and histology served as a normal 
control group. All biopsies were prepared and embedded 
in paraffin routinely. Sections were cut at a thickness of 
4 μm and then stained with hematoxylin and eosin (H&E). 
Basic information was summarized in Table 1. This study 
was approved by the local Medical Research Committee. 
Immunohistochemistry (IHC) for stem-like 
markers, stromal proliferative activity labeled 
by PCNA and stromal fibroblasts labeled by 
vimentin
Sections for IHC were deparaffinized in xylene, 





 solution in methanol for 15 minutes to block 
endogenous peroxidases. Antigen retrieval was achieved 
by boiling sections for 15 minutes in 0.01 M citrate 
buffer, pH 6.0. Nonspecific binding was blocked by 
incubating sections in phosphate buffered saline (PBS) 
containing 4% normal bovine serum and 0.25% Triton-X 
100. The slides were rinsed three times with PBS with 
0.25% Triton-X 100 (PBS-T) for 5 min and incubated 
overnight at 4 0C with different antibodies for putative 
stem-like markers: anti-Msi (DAKO, Carpinteria, CA, 
USA), anti-CD133 (Abcam, Cambridge, UK), anti-
LGR5 (MBL International, Woburn, MA 01801, USA) 
and anti-ALDH1 (BD Bioscience, San Jose, CA, USA) 
individually. For PCNA and vimentin IHC, sections were 
incubated overnight at 4°C with primary antibodies: anti-
PCNA polyclonal antibody (Abcam, Cambridge, UK) and 
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anti-Vimentin monoclonal antibody (DAKO, Carpinteria, 
CA, USA), respectively. After primary antibody staining, 
the slides were washed with PBS-T for 10 minutes, and 
detection was performed using the Vectastain Elite ABC 
Kit (Vector Lab., Burlingame, CA, USA) according to 
the manufacturer’s instructions and our published method 
[14, 15]. Next, 3-Amino-9-ethylcarbazole (AEC; Vector 
Laboratories, Burlingame, CA, USA) was used as the 
chromogen, and slides were counterstained with Mayer’s 
hematoxylin. Negative control slides for IHC were 
made routinely: (1) primary antibodies were substituted 
with the isotype-matched control antibodies; and (2) a 
secondary antibody was substituted with PBS-T.
Double IHC for the examination of proliferative 
activity in stromal fibroblasts
Because fibroblasts are the main type of tumor stromal 
cells [44], we examined the proliferative activity of fibroblasts 
with double IHC in the tumor stroma. Double IHC with PCNA/
Vimentin (to label fibroblasts) antibodies was performed using 
the EnVision Doublestain System kit (DAKO, Carpinteria, CA, 
USA) according to the manufacturer’s instructions and our 
published methods [45, 46]. In brief, the slides were incubated 
overnight at 4ºC with anti-PCNA antibody after antigen 
retrieval and then incubated with labeled polymer-horseradish 
peroxidase-anti-mouse and anti-rabbit antibodies for 30 
minutes at room temperature. Peroxidase activity was detected 
with the enzyme substrate 3,3′-diaminobenzidine tetrachloride 
(DAB). After quenching the enzyme reaction, the slides were 
incubated in Doublestain Block at room temperature for 5 
minutes to block endogenous phosphatases. The slides were 
then incubated with anti-Vimentin antibody for 2 hours at room 
temperature. After washing, the slides were incubated with 
labeled polymer-alkaline phosphatase anti-mouse and anti-
rabbit antibodies for 30 minutes at room temperature. A Fast 
Red chromogen substrate solution was used to visualize anti-
vimentin antibody. The sections were slightly counterstained 
with Mayer’s hematoxylin.
Morphological evaluation
The semi-quantified density grading of stem-like 
positive cells was employed according to the method 
described in our previous publication [45, 47]. In brief, 
semi-quantitative scoring was conducted in at least five well-
orientated fields with abundant positive cell distribution from 
each slide under 400 × high-power magnification. In the 
adenoma/CRC epithelium, the number of LGR5 positive and 
ALDH1 positive cells was graded on a scale of 0–3: grade 
0 indicated an absence of LGR5/ALDH1 positive cells; 
grade 1 indicated a 1%–5% presence of LGR5/ALDH1 
positive cells; grade 2 indicated a 6%–25% presence of 
LGR5/ALDH1 positive cells; and grade 3 indicated a 
26%–100% presence of LGR5/ALDH1 positive cells. The 
results were grouped as positive (grade 2 or 3), or negative 
(grade 0 or 1), given that the normal gastric mucosa was 
identified as grade 1 for LGR5/ALDH1 expression [48]. 
In tumor stroma, fibroblasts (labeled by Vimentin) were 
found at a very high density and were evaluated with 
light microscopy using the following criteria described by 
Adegboyega et al. [49]: negative immunoreactivity (IR) 
(−), 1% to 25% positive cells (+), 25% to 50% positive cells 
(++), and greater than 50% positive cells (+++). The number 
of PCNA positive (nucleus) cells in the tumor stroma 
were counted in at least 5 optional fields with abundant 
distribution from each slide under a 400 × high-power 
magnification. The average values were used for statistical 
analysis.
Statistical analysis 
The results were expressed as the mean ± SEM 
unless otherwise stated. Statistical significance was 
evaluated by the Mann–Whitney and Kruskal–Wallis 
tests. Values of P < 0.05 were considered significant.
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Table 1: Basic histological information of patients and normal individuals 
N Location Histopathology Dysplasia degree
colon rectum tubular tubulovillous LGD HGD
Normal 12 5 7
Adenoma 30 20 10 20 10 18 12
TNM stage
adenocarcinoma I II III
CRC 30 16 14 30 7 10 13
LGD: low grading of dysplasia.
HGD: high grading of dysplasia.
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